SufA - a bacterial enzyme that cleaves fibrinogen and blocks fibrin network formation.

Microbiology
Christofer KarlssonInga-Maria Frick

Abstract

Finegoldia magna is a member of the normal human bacterial flora on the skin and other non-sterile body surfaces, but this anaerobic coccus is also an important opportunistic pathogen. SufA was the first F. magna proteinase to be isolated and characterized. Many bacterial pathogens interfere with different steps of blood coagulation, and here we describe how purified SufA efficiently and specifically cleaves fibrinogen in human plasma. SufA is both secreted by F. magna and associated with the bacterial surface. Successful gene targeting has previously not been performed in anaerobic cocci, but in order to study the role of the SufA that is present at the bacterial surface, we constructed an F. magna mutant that expresses a truncated SufA lacking proteolytic activity. In contrast to wild-type bacteria that delayed the coagulation of human plasma, mutant bacteria had no such effect. Wild-type and mutant bacteria adhered to keratinocytes equally well, but in a plasma environment only wild-type bacteria blocked the formation of fibrin networks surrounding adherent bacteria. The effective cleavage of fibrinogen by SufA suggests that the interference with fibrin network formation represents an adaptive mechanism of F. magna with pote...Continue Reading

References

Aug 1, 1990·American Journal of Surgery·T M SinghC K Zarins
Feb 23, 1990·JAMA : the Journal of the American Medical Association·L A Liotta, E Kohn
Jul 1, 1989·Clinical Microbiology Reviews·V A Fischetti
Mar 1, 1986·The Journal of Clinical Investigation·R M SeniorG D Wilner
Oct 25, 1996·The Journal of Biological Chemistry·M de ChâteauL Björck
Sep 1, 1996·Zentralblatt Für Bakteriologie : International Journal of Medical Microbiology·A E Flores, P Ferrieri
Feb 11, 1998·Clinical Microbiology Reviews·D A Murdoch
Feb 11, 1998·The Journal of Investigative Dermatology·N HunzelmannR Nischt
Sep 16, 1999·International Journal of Dermatology·P G Bowler, B J Davies
Nov 5, 1999·The Journal of Biological Chemistry·E CamererH Prydz
Mar 10, 2000·Biochimica Et Biophysica Acta·J Travis, J Potempa
Jun 5, 2001·Blood·A F DrewJ L Degen
Jul 20, 2001·Annals of the New York Academy of Sciences·J W Weisel, L Medved
Nov 20, 2002·Infection and Immunity·Yi-Quan TangMichael E Selsted
Jun 6, 2003·Cellular and Molecular Life Sciences : CMLS·R Bals, J M Wilson
Aug 16, 2003·Blood·Brian J RybarczykPatricia J Simpson-Haidaris
Apr 20, 2005·Advances in Protein Chemistry·John W Weisel
Aug 17, 2005·Journal of Thrombosis and Haemostasis : JTH·M W Mosesson
May 13, 2006·Journal of Thrombosis and Haemostasis : JTH·N LaurensM P M de Maat
Jan 9, 2007·Blood Reviews·Alisa S Wolberg
Jan 31, 2007·The Journal of Infectious Diseases·Arne EgestenLars Bjorck
May 8, 2007·Biochemical and Biophysical Research Communications·Chunli LiuKeiji Hasumi
Dec 1, 2007·Microbiology·Christofer KarlssonInga-Maria Frick
Feb 12, 2008·DNA Research : an International Journal for Rapid Publication of Reports on Genes and Genomes·Takatsugu GotoShigeru Akimoto

❮ Previous
Next ❯

Citations

Aug 29, 2014·Molecular Microbiology·Elizabeth C MurphyInga-Maria Frick
Oct 4, 2012·FEMS Microbiology Reviews·Elizabeth Carmel Murphy, Inga-Maria Frick

❮ Previous
Next ❯

Datasets Mentioned

BETA
U50978
DQ679960

Methods Mentioned

BETA
ion-exchange
gel filtration
PCR
ELISA
electron microscopy
scanning electron microscopy
transmission electron microscopy

Software Mentioned

MASCOT

Related Concepts

Related Feeds

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.